Company: IXHL
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001213900-25-036057
Chunk: 19

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 19
---
 Listing Rule 5635(d), stockholder approval is required prior to the issuance of securities in connection with a transaction (or a series of related transactions) other than a public offering involving the sale, issuance or potential issuance of common stock (or securities convertible into or exercisable for common stock) equal to 20% or more of the common stock or 20% or more of the voting power outstanding before the issuance at a price that is less than the lower of (i) the “Nasdaq Official Closing Price” (as reflected on Nasdaq.com) immediately preceding the signing of the binding agreement for such issuance; or (ii) the average “Nasdaq Official Closing Price” of the common stock (as reflected on Nasdaq.com) for the five trading days immediately preceding the signing of the binding agreement for such issuance. This price is referred to as the “Minimum Price.” This Proposal No. 1 is requesting approval pursuant to Nasdaq Listing Rule 5635(d) and not any other section of Nasdaq Listing Rule 5635. Required Approvals for the Exercise of the Series A Warrants The terms of the Series A Warrants require that we seek stockholder approval as may be required by the rules and regulations of the Nasdaq Stock Market LLC for their exercise and certain adjustments set forth therein. Accordingly, we are seeking stockholder approval of the following (the “Warrant Stockholder Approval”): (a)to consent to any adjustment to the exercise price (as low as the Floor Price of $0.216 per share) and/or number of shares of common stock underlying the Series A Warrants (from 11,574,090 to up to 115,740,900, assuming full adjustment of the exercise price to the Floor Price and beforegiving effect 11 to the zero exercise price provision and up to 347,222,700 assuming full adjustment of the exercise price to the Floor Price and aftergiving effect to the zero exercise price provision) in the event of an adjustment upon the Adjustment Date (i.e. the close of trading on the 11 thtrading day after the Release Date, which is the later of the date the Warrant Shares may be resold pursuant to an effective registration statement or Rule 144 and the date of the Warrant Stockholder Approval), as defined and described below, without regard to any limitations upon exercise of the Series A Warrants relating to the Warrant Stockholder Approval and/or the provisions prohibiting adjustments in such Series A Warrants above the Floor